Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC warnings not prominent

This article was originally published in The Tan Sheet

Executive Summary

A study examining "the conspicuousness and prominence of two required warnings on OTC pain relievers" suggests labels ineffectively communicate warnings about tamper evidence and child-resistance features. Researchers led by Laura Bix of the School of Packaging at Michigan State University found fewer than 20 percent of 61 participants looked at tamper evidence warnings on five OTC acetaminophen products. Fewer than half looked at child-resistant feature warnings, according to the March 30 study in the Proceedings of the National Academy of Sciences. Further, the warnings were the least legible part of the label, and brand name and claims were most legible. The findings suggest the warnings are not "prominent" or "conspicuous" as required by FDA regulations. However, researchers say consumers do not consider the warnings important and additional consumer education is needed

You may also be interested in...

Warning Letter Close-Outs – March 2020

The US FDA released five device-related close-out letters in March.

Medicines Must Be Designated As Priority Items, Says IGBA

Governments around the world should designate all medicines as ‘priority essential products’, the IGBA has urged, as a surge in demand coinciding with a reduction in the number of flights and rising freight costs are making it more difficult for suppliers to meet global requirements amid the coronavirus pandemic.

COVID-19: FDA Will Hold Remote Meetings With Firms, Extends Marketing Application Due Dates

In a letter to the medtech industry, the FDA’s William Maisel says the US agency will hold remote meetings with device makers and other stakeholders through the end of May. The FDA also extended due dates for marketing applications by 90 days.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts